Preclinical Data On Neuralstem’s Genetically Modified HK532-IGF-1 Stem Cells … – PR Newswire (press release)
Smarter Analyst |
Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells …
PR Newswire (press release) GERMANTOWN, Md., June 26, 2015 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, … Company Update (NYSE MKT:CUR): Preclinical Data On Neuralstem, Inc.'s … Neuralstem up 11% premarket on preclinical Alzheimer's data (CUR) Short Interest in Neuralstem Drops By 5.6% (CUR) |
